From idea to certified medical product - we help innovators bring safe, compliant, investable and scalable devices to market faster.
Consonance is a one-stop medical device development company.
We design and develop innovative medical devices, transforming the visions of doctors, engineers and businesses into successful medical products. Our team of qualified MedTech engineers, scientists, regulatory and certification consultants provides hands-on experience to accompany innovators from concept to industrialization.
Our mission is to improve the quality of life by creating and delivering innovative and reliable medical devices. Our passion translates into real results.
We partner both with ambitious start-ups, dynamic SMEs and renowned international companies to jointly create innovative medical solutions. Being ISO 13485:2016 certified in the area of medical device design, development and manufacturing, we ensure that medical products we develop, meet MDR and FDA regulatory standards.
Why us?
We are tech partners for two Catalonian MedTech startups.
We are the EIC BAS partners for MedTech projects.
We put 3 medical innovations into production in 2023.
Our work won 1st and 2nd place in the Huawei Startup Challenge.
We believe that together we can change the future of healthcare!
With over 50 years of experience offering solutions, with a strong background as an ABS manufacturer, we have become a reliable and valued material supplier for our customers. Our track record reflects our adaptability, constant growth and strong commitment to quality and tailor-made solutions. We offer reliable, high-quality solutions specifically designed for the medical sector, meeting the most stringent requirements in terms of safety and performance. Our compounds are validated according to ISO 10993 and USP Class VI. At ELIX, we work with leading pharmaceutical and injection moulding companies to develop materials that combine technical efficiency, regulatory compliance and a strong commitment to sustainability.
Pre-coloured ABS plastics are widely used materials in external enclosures applications of medical devices.
Especially in parenteral drug de livery medical devices (medical devices designed to deliver a specific medicine to the patient through parenteral paths e.g. via mucosa (e.g. absorption through the lungs) or IV), biocompatibility is a key property that needs to be complied to fulfil with medical regulations (e.g. EU MDR or US FDA regulatory requirements). Final medical devices must be tested according to ISO 10993 and it is the responsibility of the Medical OEM manufacturer to make sure that such tests are conducted and passed. Biocompatibility tests are expensive and there is the risk that the required medical device may not pass one or more of them. The implementation of specific production procedures like GMPs (Good Manufacturing Practices), clean rooms etc. is critical, but positive test results cannot be assured without the correct pre-selection of all materials needed to produce each component of the device.
In addition, medical device bright and intense colours are relevant for patients because they stimulate a positive attitude to take the drug medication, they help the distinction of different device part and facilitate the way how to use the device itself. They help to distinguish different types of drugs that are targeting to different types of diseases. Despite colour in medical device applications is such a key property, there are strict regulatory limitations in the type of pigments admitted in the colour formulations, and in their maximum allowed concentrations. When the biocompatibility requirement according to ISO 10993 must be met, not only the base ABS material must be biocompatible but also all the additives compounded with the material, including the colour formulation with all its different pigments. No biocompatible pigments must be directly excluded, and maximum allowed pigment concentrations must not be exceeded. Furthermore, special attention must be given to possible mutual interactions among different pigments, ABS material and other additives. ELIX Polymers eliminates those risks to OEMs, processors and developers providing a medical precoloured ABS material formulation that includes the complete colour recipe and does not need any further material modification. The complete formulation has been fully reviewed and pre-tested to meet biocompatibility according to ISO 10993 and other regulatory requirements. This is a much safer approach for medical OEMs and moulders instead of choosing a medical ABS in natural colour and compound it themselves with a masterbatch colour, during the injection moulding process.
fetaLife Technologies is a medtech spin-off of the SJD Barcelona Children's Hospital, the Hospital Clínic and the Unniversitat de Barcelona, dedicated to the development of a Fetal Liquid Incubator, a disruptive solution for extremely premature babies (22–26 weeks of gestation).
Inbrooll Industries S.L. is a multidisciplinary engineering company specialized in the development of advanced technological devices, supporting clients from early concept to industrialization and production readiness.
Through its Indooit 360° methodology, Inbrooll ensures a structured and efficient development process, integrating electronics, mechanics, and microfluidics into robust and scalable solutions.
With a strong track record in healthcare, biotechnology, and scientific instrumentation, Inbrooll operates under ISO 13485, ISO 9001, and ISO 14001 certifications, guaranteeing high standards of quality and regulatory compliance.
Inbrooll acts as a strategic partner for companies seeking to transform innovative ideas into manufacturable and market-ready products.
We partner with MedTech, biotech and industrial companies developing new devices, helping them move efficiently from concept and prototyping to industrialization and production.
With a strong end-to-end approach and expertise in electronics, mechanics and microfluidics, we turn complex developments into robust, scalable and market-ready solutions—reducing risk and accelerating time to market under ISO 13485, ISO 9001 and ISO 14001 standards.
Inteplast Medical, a division of Inteplast S.A., specializes in the design and manufacture of high-quality plastic solutions for the medical, pharmaceutical, and veterinary sectors. With over 50 years of experience and facilities in Spain and the Czech Republic, we operate a 1,500 m² ISO Class 8 clean room in Catalonia. Our capabilities include thermoplastic injection molding, overmoulding, bi-material injection, and final product assembly. Production is carried out under a sanitary license validated by AEMPS. We offer integrated, customized solutions, supporting our clients from concept to industrialization while ensuring compliance with the highest technical and regulatory standards.
Novella is a non-invasive tool for evaluating blood flow in hepatopancreatobiliary and transplant surgeries.
Our software allows surgeons and their teams to predict surgical outcomes before the first incision, leading to better results, greater safety, and a reduction in complications and associated costs up to 500%.
Qrem is a start-up founded in Barcelona in 2016 engaged to regenerative medicine that develops, manufactures and markets medical devices.
Its mission is to promote the standardization and scalability of autologous regenerative therapies, making available to physicians Lab-in-a-Box bioengineering systems to carry out these therapies in their own offices in an easy and closed way so that due to their cost-effectiveness, they reach the largest number of patients possible.
Qrem Cytokine, the company's first product to be marketed since 2018, automates and standardizes the production of an Autologous Cytokine-Rich Serum (ACRS) from a patient's blood.
Healthcare professionals can treat various indications requiring tissue repair or regeneration by locally injecting the ACRS into the treatment area.
Qrem currently markets its products in 11 European countries and is working to position ACRS as a premium treatment for tendinopathies and wound care, aiming for exponential international growth. For this reason, it is seeking a €2 million Series A funding round.
